The first studies on CRISPR/Cas9 on CF were carried out in 2013 by Schwank et al. (2013), in which they tested the recovery of functional CFTR in intestinal organoids obtained from CF patients, and proved the repairing of the mutation at the CFTR locus with CRISPR/Cas9 gene editing. The gene discussed is CFTR; the disease is cystic fibrosis.